Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future

Table 3 Summary of treatment in severe acute respiratory syndrome coronavirus-2 positive patients with stable inflammatory bowel disease disease course

Drug	Suggestions	Additional comments
	Continue therapy
Salicylates	Yes	A pause can be considered since data suggest a possible association of their use and poor COVID-19 outcome
Locally acting steroids	Yes	No data available
Systemic steroids	Rapid tapering	Dosage below 40 mg/d is suggested along with rapid tapering, particularly in patients without pneumonia and need for oxygen supplementation
Azathioprine	No	Delay treatment for 2 wk and/or until COVID-19 symptoms resolve
Methotrexate	No	Delay treatment for 2 wk and/or until COVID-19 symptoms resolve
Anti-TNF	No	Delay treatment for 2 wk and/or until COVID-19 symptoms resolve. Continued therapy may be considered in selected patients since no data demonstrated adverse outcome to date.
Vedolizumab, anti-IL-12/23	No	Delay treatment for 2 wk and/or until COVID-19 symptoms resolve
Janus kinase inhibitors	No	Delay treatment for 2 wk and/or until COVID-19 symptoms resolve

COVID-19: Coronavirus disease 2019; IL: Interleukin; TNF: Tumor necrosis factors.